Sarcopenic ObesityChaRExNCT06671847
Feasibility of At-Home Chair-Based Resistance Band Training to Improve Balance, Strength, and Bone Density in Older Adults
A study testing THERABand resistance exercise bands in people with Sarcopenic Obesity, run by The University of Texas Health Science Center, Houston at 1 site in United States.
Trial summary
The purpose of this study is to determine the feasibility of implementing a 24-week at-home chair-based resistance band training intervention, to determine effectiveness of a the a 24-week at-home chair-based resistance band training intervention in improving body composition and to determine the effectiveness of a… Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Sarcopenic Obesity
- What is being tested?
- THERABand resistance exercise bands
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 11 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Mar 2025to 7 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- English-speaking
- receive care at the UT Physician Center for Healthy Aging
Who cannot join
- inability to provide informed consent on their own
- presence of obvious signs of cognitive decline
- a diagnosis of dementia and inability to come to the clinic for the scheduled study visits.
Trial locations and contacts
1 site in 1 country.
United States1 site
The University of Texas Health Science Center at Houston
Houston, Texas, 77479
About this study
Official title: Feasibility of 24-Weeks of At-Home Chair-Based Resistance Band Training to Improve Balance, Strength, and Bone Density in Older Adults (ChaREx Study)
The purpose of this study is to determine the feasibility of implementing a 24-week at-home chair-based resistance band training intervention, to determine effectiveness of a the a 24-week at-home chair-based resistance band training intervention in improving body composition and to determine the effectiveness of a 24-week at-home chair-based resistance band training intervention in improving physical performance in adults 50 years and older, receiving care at the UT Physicians Center for Healthy Aging.
- Conditions
- Sarcopenic Obesity
- Being tested
- THERABand resistance exercise bands
- Keywords
- chair-based resistance band exercise
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
THERABand resistance exercise bandsDevice
The training will be performed using THERABand resistance exercise bands.Participants will be instructed to perform the exercises twice per week at home, for the 24 weeks duration. Each exercise session will entail 1 set of 15 repetitions of 9 different exercises
| Study group | Role | What they receive |
|---|---|---|
| Chair-based resistance band training | Experimental | Not described Receives: Device: THERABand resistance exercise bands |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility as assessed by the number of people who are able to follow the prescribed exercise regimen at least 50 percent of the time
Measured: end of study (24 weeks from baseline)
Secondary outcomes (20)
Change in body fat
This will be assessed using the handheld bioelectrical impedance analysis (BIA) device (Omron HBF-510)
Measured: baseline,6-months
Change in bone mineral density (BMD) of the femoral neck and lumbar spine
This will be assessed by the Dual energy x-ray absorptiometry (DXA)
Measured: baseline, 1 year from baseline
Handgrip strength
This will be assessed using a validated handgrip dynamometer
Measured: baseline
Handgrip strength
This will be assessed using a validated handgrip dynamometer
Measured: 1-month
Handgrip strength
This will be assessed using a validated handgrip dynamometer
Measured: 3-months
Handgrip strength
This will be assessed using a validated handgrip dynamometer
Measured: 6-months
60-second balance as assessed by the the Zibrio Stability Pro scale
This is determined by the patient standing on the Zibrio Stability Pro Scale unassisted for one minute and will be measured on a scale of 1 to 9 with lower scores indicating higher risk of fall
Measured: Baseline
60-second balance as assessed by the the Zibrio Stability Pro scale
This is determined by the patient standing on the Zibrio Stability Pro Scale unassisted for one minute and will be measured on a scale of 1 to 9 with lower scores indicating higher risk of fall
Measured: 1-month
60-second balance as assessed by the the Zibrio Stability Pro scale
This is determined by the patient standing on the Zibrio Stability Pro Scale unassisted for one minute and will be measured on a scale of 1 to 9 with lower scores indicating higher risk of fall
Measured: 3-months
60-second balance as assessed by the the Zibrio Stability Pro scale
This is determined by the patient standing on the Zibrio Stability Pro Scale unassisted for one minute and will be measured on a scale of 1 to 9 with lower scores indicating higher risk of fall
Measured: 6-months
walking gait speed
Gait speed will be assessed over a 6-meter distance measured within a private clinic space. The participant will be instructed to walk at their normal walking pace (as if they were walking throughout the house) and the distance/time will be converted to meters/second.Faster walking speed is related to reduced fall-risk, improved physical function, and greater survival .
Measured: Baseline
walking gait speed
Gait speed will be assessed over a 6-meter distance measured within a private clinic space. The participant will be instructed to walk at their normal walking pace (as if they were walking throughout the house) and the distance/time will be converted to meters/second.Faster walking speed is related to reduced fall-risk, improved physical function, and greater survival .
Measured: 1-month
walking gait speed
Gait speed will be assessed over a 6-meter distance measured within a private clinic space. The participant will be instructed to walk at their normal walking pace (as if they were walking throughout the house) and the distance/time will be converted to meters/second.Faster walking speed is related to reduced fall-risk, improved physical function, and greater survival .
Measured: 3-months
walking gait speed
Gait speed will be assessed over a 6-meter distance measured within a private clinic space. The participant will be instructed to walk at their normal walking pace (as if they were walking throughout the house) and the distance/time will be converted to meters/second.Faster walking speed is related to reduced fall-risk, improved physical function, and greater survival .
Measured: 6-months
Blood level of pro-collagen type 1 N-telopeptide (P1NP)
P1NP is a metabolic marker of bone formation, indicates status of bone loss and a stable or decreased level will be indicating improved metabolism
Measured: Baseline
Blood level of pro-collagen type 1 N-telopeptide (P1NP)
P1NP is a metabolic marker of bone formation, indicates status of bone loss and a stable or decreased level will be indicating improved metabolism
Measured: 6 months
Frailty as assessed by the Fried criteria
This consists of 5 items (unintentional weight loss, weakness [low grip strength], slowness low, self-reported exhaustion and low physical activity). Patients who meet 1or 2 of the criteria are described as pre-frail and 3 or more as frail.
Measured: Baseline
Frailty as assessed by the Fried criteria
This consists of 5 items (unintentional weight loss, weakness [low grip strength], slowness low, self-reported exhaustion and low physical activity). Patients who meet 1or 2 of the criteria are described as pre-frail and 3 or more as frail.
Measured: 1-month
Frailty as assessed by the Fried criteria
This consists of 5 items (unintentional weight loss, weakness [low grip strength], slowness low, self-reported exhaustion and low physical activity). Patients who meet 1or 2 of the criteria are described as pre-frail and 3 or more as frail.
Measured: 3-months
Frailty as assessed by the Fried criteria
This consists of 5 items (unintentional weight loss, weakness [low grip strength], slowness low, self-reported exhaustion and low physical activity). Patients who meet 1or 2 of the criteria are described as pre-frail and 3 or more as frail.
Measured: 6-months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Nov 2024
- Study start5 Mar 2025
- Primary completion7 Jan 2026
- Study completion7 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sarcopenic ObesityStudies of the same condition, open and under way.
- More trials run by The University of Texas Health Science Center, HoustonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 11 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nuzha Amjad, The University of Texas Health Science Center, Houston
- Investigators
- Nuzha Amjad, MD, Principal investigator, The University of Texas Health Science Center, Houston
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06671847
- Sponsor's protocol ID
- HSC-MS-24-0485
- Acronym
- ChaREx
- Status last verified
- Aug 2026
- First submitted
- 1 Nov 2024
- Last updated
- 14 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility of 24-Weeks of At-Home Chair-Based Resistance Band Training to Improve Balance, Strength, and Bone Density in Older Adults (ChaREx Study)
- ClinicalTrials.gov ID
- NCT06671847
- Acronym / sponsor ID
- ChaREx / HSC-MS-24-0485
- Conditions
- Sarcopenic Obesity
- Keywords
- chair-based resistance band exercise
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 11 participants (actual)
- Lead sponsor
- The University of Texas Health Science Center, HoustonUniversity, hospital or other
- Study start
- 5 Mar 2025 (actual)
- Primary completion
- 7 Jan 2026 (actual)
- Study completion
- 7 Jan 2026 (actual)
- First posted
- 4 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the feasibility of implementing a 24-week at-home chair-based resistance band training intervention, to determine effectiveness of a the a 24-week at-home chair-based resistance band training intervention in improving body composition and to determine the effectiveness of a 24-week at-home chair-based resistance band training intervention in improving physical performance in adults 50 years and older, receiving care at the UT Physicians Center for Healthy Aging.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Chair-based resistance band training | Experimental | Device: THERABand resistance exercise bands |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- English-speaking
- receive care at the UT Physician Center for Healthy Aging
Key exclusion criteria (3 listed)
- inability to provide informed consent on their own
- presence of obvious signs of cognitive decline
- a diagnosis of dementia and inability to come to the clinic for the scheduled study visits.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| THERABand resistance exercise bandsThe training will be performed using THERABand resistance exercise bands.Participants will be instructed to perform the exercises twice per week at home, for the 24 weeks duration. Each exercise session will entail 1 set of 15 repetitions of 9 different exercises | Device | Chair-based resistance band training |
Primary outcome
Feasibility as assessed by the number of people who are able to follow the prescribed exercise regimen at least 50 percent of the time
Time frame: end of study (24 weeks from baseline)
20 secondary outcomes
Change in body fat
Time frame: baseline,6-months
Change in bone mineral density (BMD) of the femoral neck and lumbar spine
Time frame: baseline, 1 year from baseline
Handgrip strength
Time frame: baseline
Handgrip strength
Time frame: 1-month
Handgrip strength
Time frame: 3-months
Handgrip strength
Time frame: 6-months
60-second balance as assessed by the the Zibrio Stability Pro scale
Time frame: Baseline
60-second balance as assessed by the the Zibrio Stability Pro scale
Time frame: 1-month
60-second balance as assessed by the the Zibrio Stability Pro scale
Time frame: 3-months
60-second balance as assessed by the the Zibrio Stability Pro scale
Time frame: 6-months
walking gait speed
Time frame: Baseline
walking gait speed
Time frame: 1-month
walking gait speed
Time frame: 3-months
walking gait speed
Time frame: 6-months
Blood level of pro-collagen type 1 N-telopeptide (P1NP)
Time frame: Baseline
Blood level of pro-collagen type 1 N-telopeptide (P1NP)
Time frame: 6 months
Frailty as assessed by the Fried criteria
Time frame: Baseline
Frailty as assessed by the Fried criteria
Time frame: 1-month
Frailty as assessed by the Fried criteria
Time frame: 3-months
Frailty as assessed by the Fried criteria
Time frame: 6-months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Sarcopenic Obesity
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity
Active, not recruitingObservational study
Dietary Intake, Sarcopenic Obesity, and Other Treatment-Related Outcomes in Indian Children With Acute Lymphoblastic Leukemia
Sarcopenic Obesity
RecruitingObservational study
Investigating the Link Between Advanced Glycation End Products (AGEs) and Muscle Wasting in Sarcobesity
Sarcopenia, Obesity
Not yet recruiting
Effects of the EatWelLog App on Enhancing Diet Management for Older Adults With Sarcopenic Obesity
Sacropenic Obesity
RecruitingObservational study
GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes
Obesity, Sarcopenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nuzha Amjad, MD principal investigator
The University of Texas Health Science Center, Houston
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing THERABand resistance exercise bands in people with Sarcopenic Obesity, run by The University of Texas Health Science Center, Houston at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility as assessed by the number of people who are able to follow the prescribed exercise regimen at least 50 percent of the time (time frame: end of study (24 weeks from baseline)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.